TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: suicidal ideation (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of LN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep scale score (ESS and QSQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [64Cu]Cu‐DOTATATE uptake in the coronary arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate of restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival color matching degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of alanine transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TH2A cell frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD38+ TH2A cell frequencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgG4 antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean levels of anti-factor Xa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with optimal level of anti-factor Xa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalized UQ-YBT test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder active repositioning accuracy test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Two-minute push-up test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: low-risk drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pre-treatment abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of HBV intrauterine transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-expiratory lung volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Levels of IL-6 and IL-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increment of hemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Knee extension peak torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of acupuncture in preventing MWoA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of acupuncture method
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombocytopenia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median Gastric Fluid Volume (GFV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of neonates developing hyponatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of neonates developing hypernatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants receiving colorectal cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants receiving lung cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sino-Nasal Outcome Test-22 score difference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nasal mucociliary clearance time difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic adherence at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: First-attempt intubation success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glottis view (Cormack–Lehane view 1–2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of ≥ grade 2 side-effects at the extremities
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Balance functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive decline measured by CDR-SB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: increases in meaningful activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: decreases in internalizing problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrolyte imbalances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Markers of renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Abundance of mosquitoes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abundance of midges
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in total WOMAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sleep disturbances
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: all-cause death/MI/UA
Endpoint domain: Mortality/survival
Primary endpoint: Critical errors made with ELLIPTA versus BREEZHALER
Endpoint domain: Adverse events/effects
Primary endpoint: Overall errors made with ELLIPTA versus BREEZHALER
Endpoint domain: Adverse events/effects
Primary endpoint: Need for HCP instruction with ELLIPTA versus BREEZHALER
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: cognitive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general disease symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relationship well‐being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sealer penetration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patent dentinal tubules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-judgemental support and guidance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative probability of failure after tube shunt surgery
Endpoint domain: Mortality/survival
Primary endpoint: YBT anterior reach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VEGF‐A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VEGF‐C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean SPA scores
Endpoint domain: Life impact
Endpoint subdomain: Satisfaction
Primary endpoint: Duration of positive pressure support
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIM deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls per person-year
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of progressive CNS disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: LBP-hampered mobility improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first detection of AF lasting > 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fear of future isolation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Analog Scale (VAS) score for leg pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of antibiotic prescription at day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median number of days with restricted activities by day 14
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change on the PHQ-9
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change on the SDS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: VAS scores under quiescent state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS scores under active state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROM of hip flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROM of hip abduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CO2 rebreathing reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: subhealth awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Identification of urinary metabolites as biomarkers of pulse intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to treatment initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CV health by LS7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: psychological resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: levels of anxiety
Endpoint domain: Adverse events/effects
Primary endpoint: levels of depression
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HBV DNA level at week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decreased anxiety on the STAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective treatment success
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: grip force of the dominant arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: likelihood of radiographic healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD rates at follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total average anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in acute headache medication use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Part B spending
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: HDL cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total cannulation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: rates of posterior wall puncture and haematoma
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of methamphetamine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of mMASI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MELASQoL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean distance covered in the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with severe fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CHD deaths
Endpoint domain: Mortality/survival
Primary endpoint: OMAS at 12 months after syndesmotic fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications rate in RR vs ODR groups
Endpoint domain: Adverse events/effects
Primary endpoint: percent weight loss from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of participants achieving ≥5% weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary outcome of canagliflozin effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: non-supine respiratory disturbance index (RDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: reduction in calprotectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: improved Geboes score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in median pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting endogenous glucose production (EGP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin‐induced suppression of EGP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma free fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean respiratory sinus arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum plasma insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma insulin area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum glucose infusion rate (GIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Glucose infusion rate (GIR) AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Agreement on preferred repair type
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: communication and teamwork skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: interprofessional learning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Morphologically-good blastocyst formation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Duration of local respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Capillary blood saturation (SatO2,%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful treatment of insulin-induced hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incident CKD cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Composite of cardiovascular death and heart transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Composite outcome of death and vascular events
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in steroid ointment dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2Hb concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responsibility sub-dimension of professional values
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurological examination improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ulcer surface area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative ulcer culture rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement of menopausal symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Surface topography of abutments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GERD development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight loss (%TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Esophagitis incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HA performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyst formation
Endpoint domain: Adverse events/effects
Primary endpoint: Skin sinus formation
Endpoint domain: Adverse events/effects
Primary endpoint: median T-PSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dual-task balance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insomnia Disorder prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep disturbance scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep-related impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl‐Meyer Assessment‐Upper Extremity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding status at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of mouse clicks
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pixels traveled on the computer monitor
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Detection rate of sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of SLNs per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pictogram validity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of acute cholecystitis
Endpoint domain: Adverse events/effects
Primary endpoint: Median hospitalization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum TNFR2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CTP utilisation in late presenters
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days of sick leave
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean condylar inclination (degree)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Epworth Sleepiness Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visit-Specific Satisfaction Instrument-9 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to PAP therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete MPVT resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day stroke rate
Endpoint domain: Mortality/survival
Primary endpoint: Efficacy of treatment based on ETS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment based on DpR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: occurrence of local and systemic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Somnolence/sedation
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in metabolic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quadriceps contraction power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: clearance of parakeratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of inflammatory cells in epidermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral intravenous catheter failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of common early-onset TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of common early-onset TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: fraction of unbeneficial patient management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thalamus perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial secretion of active GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cartilage thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Dose response of fillers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of insomnia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum FXIIIa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease-free survival (DRFS)
Endpoint domain: Mortality/survival
Primary endpoint: anxiety-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of dexmedetomidine
Endpoint domain: Adverse events/effects
Primary endpoint: Recovery profile after sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of silent atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetic bioequivalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Public stigma reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Microaggression reduction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status